New Online Resource for People with Parkinson’s, Their Families and Carers

FLORENCE, Italy -

- Lundbeck and Teva Launch www.myPDinfo.com

Lundbeck and Teva today announce the launch of www.myPDinfo.com to provide answers to common questions following a diagnosis of Parkinson’s disease. Designed for people with Parkinson’s, their families and carers, the new site provides information on the disease itself, as well as many aspects of treatment and practical disease management such as medication, surgery, diet, exercise/physiotherapy, and emotional support.

Parkinson’s is the second most common degenerative disorder of the central nervous system and often impairs the patient’s motor skills and speech. In 2008, there were approximately 3.16 million people with Parkinson’s across the US, Japan, France, Germany, Italy, Spain and the UK and the number of people affected is set to rise as the population ages.

Maintaining a full and active life is an important part of living with PD therefore www.myPDinfo.com is focused on promoting independence and helping people with Parkinson’s to make the most of each day. There’s a section on daily living, hints and tips to help with communication, plus a number of useful tools such as downloadable medication guides and symptom diaries and links to other helpful online resources.

“The internet is fast becoming one of the most important information sources on health issues, not only for people with Parkinson’s, but also for their friends, families and the general public. Websites that contain information on all aspects of life affected by Parkinson’s are such invaluable resources, helping people remain active and therefore able to live as fulfilled a life as possible,” commented Colleen, a person with Parkinson’s living in the UK.

The easy-to-navigate website is designed as a one-stop online resource for people with Parkinson’s, their families and carers, and anyone else looking for detailed, up-to-date information about the disease. The website content was developed in cooperation with the European Parkinson’s Disease Association (EPDA) multidisciplinary review panel.

www.myPDinfo.com is produced by H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. The advice and support of the EPDA is gratefully acknowledged.

Notes to Editors:

For further media resources, please visit our social media release site: www.oursocialmedia.com/uk/h-lundbeck-as-and-teva-pharmaceutical-industries-ltd/patient_website/

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.)

For broadcast-standard video supporting this press release, please visit www.thenewsmarket.com/Lundbeck. If you are a first-time user, please take a moment to register. In case you have any questions, please email journalisthelp@thenewsmarket.com.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. It develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe. For more information, please visit www.tevapharm.com.

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and today employs over 5.500 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with CNS disorders. In 2008, the company’s revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.

Media enquiries: Burson-Marsteller (UK): Serena Thomson +44-20-7300-6411 serena.thomson@bm.com

Source: Lundbeck and Teva

Media enquiries: Burson-Marsteller (UK): Serena Thomson, +44-20-7300-6411, serena.thomson at bm.com